Biocryst Pharmaceuticals (BCRX) Cash & Current Investments (2010 - 2026)

Biocryst Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $67.7 million for Q1 2026.

• Quarterly Cash & Current Investments fell 64.42% year-over-year to $67.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.7 million (down 64.42% YoY) and the FY2025 annual result came in at $185.2 million, down 42.27% from the prior year.
• Cash & Current Investments was $67.7 million for Q1 2026 at Biocryst Pharmaceuticals, down from $185.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $443.5 million in Q1 2022 and bottomed at $67.7 million in Q1 2026.
• A 5-year average of $277.2 million and a median of $248.3 million in 2023 frame the typical range for Cash & Current Investments.
• Peak annual rise in Cash & Current Investments reached 2439.62% in 2022, while the deepest fall reached 76.16% in 2022.
• Biocryst Pharmaceuticals' Cash & Current Investments stood at $121.0 million in 2022, then soared by 221.44% to $389.0 million in 2023, then declined by 17.52% to $320.8 million in 2024, then tumbled by 42.27% to $185.2 million in 2025, then tumbled by 63.47% to $67.7 million in 2026.
• Business Quant data shows BCRX's Cash & Current Investments at $67.7 million in Q1 2026, $185.2 million in Q4 2025, and $212.9 million in Q3 2025.